Patent · US Expired

Human hematopoietic stem and progenitor cell antigen

US6455678B1 · kind B1 · utility

59Cited by
6References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 23, 1997
Grant dateSep 24, 2002
Priority date
Expiry dateApr 23, 2017

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/838
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.